268 related articles for article (PubMed ID: 31586949)
1. Original research: Second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study.
Verboon C; van den Berg B; Cornblath DR; Venema E; Gorson KC; Lunn MP; Lingsma H; Van den Bergh P; Harbo T; Bateman K; Pereon Y; Sindrup SH; Kusunoki S; Miller J; Islam Z; Hartung HP; Chavada G; Jacobs BC; Hughes RAC; van Doorn PA;
J Neurol Neurosurg Psychiatry; 2020 Feb; 91(2):113-121. PubMed ID: 31586949
[TBL] [Abstract][Full Text] [Related]
2. Second IVIg course in Guillain-Barré syndrome patients with poor prognosis (SID-GBS trial): Protocol for a double-blind randomized, placebo-controlled clinical trial.
Walgaard C; Jacobs BC; Lingsma HF; Steyerberg EW; Cornblath DR; van Doorn PA;
J Peripher Nerv Syst; 2018 Dec; 23(4):210-215. PubMed ID: 30151941
[TBL] [Abstract][Full Text] [Related]
3. Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome: an international observational study.
Verboon C; Harbo T; Cornblath DR; Hughes RAC; van Doorn PA; Lunn MP; Gorson KC; Barroso F; Kuwabara S; Galassi G; Lehmann HC; Kusunoki S; Reisin RC; Binda D; Cavaletti G; Jacobs BC; ;
J Neurol Neurosurg Psychiatry; 2021 Oct; 92(10):1080-1088. PubMed ID: 34103340
[TBL] [Abstract][Full Text] [Related]
4. Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial.
Walgaard C; Jacobs BC; Lingsma HF; Steyerberg EW; van den Berg B; Doets AY; Leonhard SE; Verboon C; Huizinga R; Drenthen J; Arends S; Budde IK; Kleyweg RP; Kuitwaard K; van der Meulen MFG; Samijn JPA; Vermeij FH; Kuks JBM; van Dijk GW; Wirtz PW; Eftimov F; van der Kooi AJ; Garssen MPJ; Gijsbers CJ; de Rijk MC; Visser LH; Blom RJ; Linssen WHJP; van der Kooi EL; Verschuuren JJGM; van Koningsveld R; Dieks RJG; Gilhuis HJ; Jellema K; van der Ree TC; Bienfait HME; Faber CG; Lovenich H; van Engelen BGM; Groen RJ; Merkies ISJ; van Oosten BW; van der Pol WL; van der Meulen WDM; Badrising UA; Stevens M; Breukelman AJ; Zwetsloot CP; van der Graaff MM; Wohlgemuth M; Hughes RAC; Cornblath DR; van Doorn PA;
Lancet Neurol; 2021 Apr; 20(4):275-283. PubMed ID: 33743237
[TBL] [Abstract][Full Text] [Related]
5. Intravenous immunoglobulin therapy for HIV-associated Guillain-Barré syndrome.
Wang J; Zhang Y; Wang M; Ren Y; Tang M; Liu L; Zhou D
Int Immunopharmacol; 2022 Nov; 112():109192. PubMed ID: 36155283
[TBL] [Abstract][Full Text] [Related]
6. IgG Fc N-glycosylation in Guillain-Barré syndrome treated with immunoglobulins.
Fokkink WJ; Selman MH; Dortland JR; Durmuş B; Kuitwaard K; Huizinga R; van Rijs W; Tio-Gillen AP; van Doorn PA; Deelder AM; Wuhrer M; Jacobs BC
J Proteome Res; 2014 Mar; 13(3):1722-30. PubMed ID: 24533874
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS).
van Doorn PA
Presse Med; 2013 Jun; 42(6 Pt 2):e193-201. PubMed ID: 23628447
[TBL] [Abstract][Full Text] [Related]
8. Dynamics and prognostic value of serum neurofilament light chain in Guillain-Barré syndrome.
van Tilburg SJ; Teunissen CE; Maas CCHM; Thomma RCM; Walgaard C; Heijst H; Huizinga R; van Doorn PA; Jacobs BC
EBioMedicine; 2024 Apr; 102():105072. PubMed ID: 38518653
[TBL] [Abstract][Full Text] [Related]
9. IVIG treatment and prognosis in Guillain-Barré syndrome.
van Doorn PA; Kuitwaard K; Walgaard C; van Koningsveld R; Ruts L; Jacobs BC
J Clin Immunol; 2010 May; 30 Suppl 1(Suppl 1):S74-8. PubMed ID: 20396937
[TBL] [Abstract][Full Text] [Related]
10. Association of Albumin Levels With Outcome in Intravenous Immunoglobulin-Treated Guillain-Barré Syndrome.
Fokkink WR; Walgaard C; Kuitwaard K; Tio-Gillen AP; van Doorn PA; Jacobs BC
JAMA Neurol; 2017 Feb; 74(2):189-196. PubMed ID: 28027337
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic factors in Guillain-Barré syndrome].
Kaida K
Rinsho Shinkeigaku; 2013; 53(11):1315-8. PubMed ID: 24291972
[TBL] [Abstract][Full Text] [Related]
12. Patient characteristics and the effects of intravenous immunoglobulin in patients with Guillain-Barre syndrome.
Guzey Aras Y; Tanik O; Dogan Güngen B; Kotan D
Ideggyogy Sz; 2016 Nov; 69(11-12):389-395. PubMed ID: 29733556
[TBL] [Abstract][Full Text] [Related]
13. Clinical features and prognosis of patients with Guillain-Barré and acute transverse myelitis overlap syndrome.
Guo F; Zhang YB
Clin Neurol Neurosurg; 2019 Jun; 181():127-132. PubMed ID: 31039494
[TBL] [Abstract][Full Text] [Related]
14. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial.
van Koningsveld R; Schmitz PI; Meché FG; Visser LH; Meulstee J; van Doorn PA;
Lancet; 2004 Jan; 363(9404):192-6. PubMed ID: 14738791
[TBL] [Abstract][Full Text] [Related]
15. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.
Lancet; 1997 Jan; 349(9047):225-30. PubMed ID: 9014908
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of complement in Guillain-Barré syndrome: the ICA-GBS study.
Davidson AI; Halstead SK; Goodfellow JA; Chavada G; Mallik A; Overell J; Lunn MP; McConnachie A; van Doorn P; Willison HJ
J Peripher Nerv Syst; 2017 Mar; 22(1):4-12. PubMed ID: 27801990
[TBL] [Abstract][Full Text] [Related]
17. The usefulness of chief complaints to predict severity, ventilator dependence, treatment option, and short-term outcome of patients with Guillain-Barré syndrome: a retrospective study.
Wang Y; Shang P; Xin M; Bai J; Zhou C; Zhang HL
BMC Neurol; 2017 Nov; 17(1):200. PubMed ID: 29157205
[TBL] [Abstract][Full Text] [Related]
18. Effect of intravenous immunoglobulin and plasmapheresis on nerve conduction parameters compared to the natural course of Guillain-Barré syndrome.
Kalita J; Mahajan R; Kumar M
J Clin Neurosci; 2024 Jul; 125():76-82. PubMed ID: 38759351
[TBL] [Abstract][Full Text] [Related]
19. Outcome of Guillain-Barré syndrome following intravenous immunoglobulin compared to natural course.
Kalita J; Misra UK; Chaudhary SK; Das M; Mishra A; Ranjan A; Kumar M
Eur J Neurol; 2022 Oct; 29(10):3071-3080. PubMed ID: 35837807
[TBL] [Abstract][Full Text] [Related]
20. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome.
Buchwald B; Ahangari R; Weishaupt A; Toyka KV
Ann Neurol; 2002 Jun; 51(6):673-80. PubMed ID: 12112071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
